- Home
- FE vs BIIB Comparison
FE vs BIIB Comparison
Compare FE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- BIIB
- Stock Information
- Founded
- FE 1996
- BIIB 1978
- Country
- FE United States
- BIIB United States
- Employees
- FE N/A
- BIIB N/A
- Industry
- FE Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FE Utilities
- BIIB Health Care
- Exchange
- FE Nasdaq
- BIIB Nasdaq
- Market Cap
- FE N/A
- BIIB 18.8B
- IPO Year
- FE N/A
- BIIB 1991
- Fundamental
- Price
- FE $39.93
- BIIB $125.00
- Analyst Decision
- FE Buy
- BIIB Buy
- Analyst Count
- FE 15
- BIIB 27
- Target Price
- FE $46.15
- BIIB $188.17
- AVG Volume (30 Days)
- FE 5.4M
- BIIB 1.3M
- Earning Date
- FE 07-29-2025
- BIIB 07-31-2025
- Dividend Yield
- FE 4.43%
- BIIB N/A
- EPS Growth
- FE 1.45
- BIIB 26.39
- EPS
- FE 1.88
- BIIB 10.12
- Revenue
- FE $13,764,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- FE $9.20
- BIIB N/A
- Revenue Next Year
- FE $3.82
- BIIB N/A
- P/E Ratio
- FE $21.36
- BIIB $12.41
- Revenue Growth
- FE 8.03
- BIIB 1.59
- 52 Week Low
- FE $37.58
- BIIB $110.04
- 52 Week High
- FE $44.97
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- FE 40.70
- BIIB 45.14
- Support Level
- FE $39.28
- BIIB $123.21
- Resistance Level
- FE $40.72
- BIIB $129.27
- Average True Range (ATR)
- FE 0.56
- BIIB 3.00
- MACD
- FE 0.01
- BIIB -0.77
- Stochastic Oscillator
- FE 40.12
- BIIB 21.06
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.